Study summaryMazdutide in phase 3: what the obesity trial reported
A dual GLP-1 and glucagon receptor agonist completed a large phase 3 trial in China. Here is what the researchers measured, in plain English.
10 October 2026 · 5 min read
Peptides, explained simply
Which peptide does
what, in plain English.
What each peptide is. What studies found. What we still don’t know.
Research reference only, not medical advice. Separate supplier links may earn us a commission at no extra cost to you.
Science without the noise
Plain English first
The science, without the jargon.
What studies found in people
Human trials clearly separated from cell and animal work.
Every claim sourced
Original papers linked, not just opinions.
Honest about the gaps
What remains unknown, stated plainly.
Latest from the library
Study summaries, methods explainers and evidence checks.
Study summaryStudy summaryTesamorelin: the trials behind an approved use abroad
Tesamorelin is one of the few peptides in this library that went through full trials and was approved in the US. What did those studies actually show?
6 October 2026 · 5 min read
Evidence checkGHK-Cu and skin: what the research has and has not shown
A copper-binding peptide found naturally in the body has a long research history in skin and wound studies. Most of it was done in the lab.
1 October 2026 · 5 min read
Compound profiles
Reference pages covering what a compound is, its proposed mechanism, the state of the published evidence and its UK regulatory status.
BPC-157Synthetic pentadecapeptide · Early research in cells and animalsCJC-1295Long-acting growth-hormone-releasing hormone analogue · Phase 1 results published; development discontinuedDSIPNine-amino-acid neuropeptide · Small historic human studies; not reproducedGHK-CuCopper-binding tripeptide · Mostly cell research, with a few small human skin studiesGHRP-2Growth hormone secretagogue · Approved as a diagnostic agent in Japan; no treatment authorisationGHRP-6Growth hormone secretagogue · Early human physiology studies only
Before you read further
Every compound covered on this site is unlicensed in the United Kingdom: it holds no MHRA marketing authorisation and is not approved for human or animal use. Published trial data describe characterised material given under medical supervision in defined study populations, and say nothing beyond that. If you have a question about your own health, a symptom or a treatment, speak to a qualified healthcare professional.
Found an error?
If we have misread a paper or missed newer work, tell us and we will correct the page.
Contact the editorial desk ›